Switching from tamoxifen to exemestane could reduce breast cancer recurrence

Jun 1, 2004

Disease-free survival in postmenopausal women with primary breast cancer significantly improved when tamoxifen monotherapy treatment was switched to exemestane therapy after 2-3 years, according to a study published in the New England Journal of Medicine. The existing treatment paradigm calls for tamoxifen, an estrogen-receptor modulator, to be taken alone for all 5 years, but some patients have experienced relapse.

Related Content

FDA Approves Second Indication for Brexafemme

December 2nd 2022

Article

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years

November 14th 2022

Article

The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.

Real-world Data Show Gardasil Protects Against Cervical, Non-Cervical Diseases

November 7th 2022

Article

The greatest reductions were seen in girls who were vaccinated when they were adolescents, with up to 73% reduction in cervical pre-cancerous lesions.

FDA Postpones Advisory Committee Meeting for OTC Birth Control

October 27th 2022

Article

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

FDA Schedules Advisory Committee Meeting for Nonprescription Birth Control

September 13th 2022

Article

If approved, Perrigo’s Opill could be the first-ever over-the-counter birth control pill. The advisory committee meeting is scheduled for Nov. 18, 2022.